Could hepatitis C-Positive kidneys be safe for transplant?
NCT ID NCT03809533
First seen Nov 06, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This study tests whether kidneys from donors with hepatitis C can be safely transplanted into people without the virus. Recipients will take the antiviral drug Epclusa for 12 weeks to prevent or treat infection. The goal is to see if this approach is safe and effective, potentially increasing the number of available kidneys for transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sofosbuvir/Velpatasvir (Epclusa)
What this could lead to
If successful, this could expand the donor pool for kidney transplants by safely using organs from hepatitis C-positive donors.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. There is a risk of HCV transmission or side effects from the antiviral drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.